<author><surname>Nathan</surname> <given-names>DM</given-names> </author><author><surname>Buse</surname> <given-names>JB</given-names> </author><author><surname>Davidson</surname> <given-names>MB</given-names> </author><title>Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes</title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>193</fpage><lpage>203</lpage>
<author><surname>Akalin</surname> <given-names>S</given-names> </author><author><surname>Berntorp</surname> <given-names>K</given-names> </author><author><surname>Ceriello</surname> <given-names>A</given-names> </author><title>Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control</title><source>Int J Clin Pract</source><year>2009</year><volume>63</volume><fpage>1421</fpage><lpage>1425</lpage>
<author><surname>Albarrak</surname> <given-names>AI</given-names> </author><author><surname>Luzio</surname> <given-names>SD</given-names> </author><author><surname>Chassin</surname> <given-names>LJ</given-names> </author><author><surname>Playle</surname> <given-names>RA</given-names> </author><author><surname>Owens</surname> <given-names>DR</given-names> </author><author><surname>Hovorka</surname> <given-names>R</given-names> </author><title>Associations of glucose control with insulin sensitivity and pancreatic beta-cell responsiveness in newly presenting type 2 diabetes</title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>198</fpage><lpage>203</lpage>
<author><surname>Heinemann</surname> <given-names>L</given-names> </author><author><surname>Chantelau</surname> <given-names>EA</given-names> </author><author><surname>Starke</surname> <given-names>AA</given-names> </author><title>Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin</title><source>Diabete Metab</source><year>1992</year><volume>18</volume><fpage>21</fpage><lpage>24</lpage>
<author><surname>Becker</surname> <given-names>RH</given-names> </author><title>Insulin glulisine complementing basal insulins: a review of structure and activity</title><source>Diabetes Technol Ther</source><year>2007</year><volume>9</volume><fpage>109</fpage><lpage>121</lpage>
<author><surname>Becker</surname> <given-names>RH</given-names> </author><author><surname>Frick</surname> <given-names>AD</given-names> </author><title>Clinical pharmacokinetics and pharmacodynamics of insulin glulisine</title><source>Clin Pharmacokinet</source><year>2008</year><volume>47</volume><fpage>7</fpage><lpage>20</lpage>
<author><surname>Becker</surname> <given-names>RH</given-names> </author><author><surname>Frick</surname> <given-names>AD</given-names> </author><author><surname>Burger</surname> <given-names>F</given-names> </author><author><surname>Potgieter</surname> <given-names>JH</given-names> </author><author><surname>Scholtz</surname> <given-names>H</given-names> </author><title>Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects</title><source>Exp Clin Endocrinol Diabetes</source><year>2005</year><volume>113</volume><fpage>435</fpage><lpage>443</lpage>
<author><surname>Heise</surname> <given-names>T</given-names> </author><author><surname>Nosek</surname> <given-names>L</given-names> </author><author><surname>Spitzer</surname> <given-names>H</given-names> </author><title>Insulin glulisine: a faster onset of action compared with insulin lispro</title><source>Diabetes Obes Metab</source><year>2007</year><volume>9</volume><fpage>746</fpage><lpage>753</lpage>
<author><surname>Luzio</surname> <given-names>S</given-names> </author><author><surname>Peter</surname> <given-names>R</given-names> </author><author><surname>Dunseath</surname> <given-names>GJ</given-names> </author><author><surname>Mustafa</surname> <given-names>L</given-names> </author><author><surname>Owens</surname> <given-names>DR</given-names> </author><title>A comparison of preprandial insulin glulisine versus insulin lispro in people with type 2 diabetes over a 12-h period</title><source>Diabetes Res Clin Pract</source><year>2008</year><volume>79</volume><fpage>269</fpage><lpage>275</lpage>
<author><surname>Becker</surname> <given-names>RH</given-names> </author><author><surname>Frick</surname> <given-names>AD</given-names> </author><author><surname>Burger</surname> <given-names>F</given-names> </author><author><surname>Scholtz</surname> <given-names>H</given-names> </author><author><surname>Potgieter</surname> <given-names>JH</given-names> </author><title>A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique</title><source>Exp Clin Endocrinol Diabetes</source><year>2005</year><volume>113</volume><fpage>292</fpage><lpage>297</lpage>
<author><surname>Becker</surname> <given-names>RH</given-names> </author><author><surname>Frick</surname> <given-names>AD</given-names> </author><author><surname>Nosek</surname> <given-names>L</given-names> </author><author><surname>Heinemann</surname> <given-names>L</given-names> </author><author><surname>Rave</surname> <given-names>K</given-names> </author><title>Dose-response relationship of insulin glulisine in subjects with type 1 diabetes</title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>2506</fpage><lpage>2507</lpage>
<author><surname>Danne</surname> <given-names>T</given-names> </author><author><surname>Becker</surname> <given-names>RH</given-names> </author><author><surname>Heise</surname> <given-names>T</given-names> </author><author><surname>Bittner</surname> <given-names>C</given-names> </author><author><surname>Frick</surname> <given-names>AD</given-names> </author><author><surname>Rave</surname> <given-names>K</given-names> </author><title>Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes</title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>2100</fpage><lpage>2105</lpage>
<author><surname>Arnolds</surname> <given-names>S</given-names> </author><author><surname>Rave</surname> <given-names>K</given-names> </author><author><surname>Hovelmann</surname> <given-names>U</given-names> </author><author><surname>Fischer</surname> <given-names>A</given-names> </author><author><surname>Sert-Langeron</surname> <given-names>C</given-names> </author><author><surname>Heise</surname> <given-names>T</given-names> </author><title>Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers</title><source>Exp Clin Endocrinol Diabetes</source><year>2010</year><volume>118</volume><fpage>662</fpage><lpage>664</lpage>
<author><surname>Porcellati</surname> <given-names>F</given-names> </author><author><surname>Rossetti</surname> <given-names>P</given-names> </author><author><surname>Busciantella</surname> <given-names>NR</given-names> </author><title>Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study</title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>2447</fpage><lpage>2452</lpage>
<author><surname>Chow</surname> <given-names>SC</given-names> </author><author><surname>Liu</surname> <given-names>JP</given-names> </author><source>Design and Analysis of Bioavailability and Bioequivalence Studies</source><year>2000</year><issue>2nd edn.</issue><other>New York</other><publisher>Marcel Dekker</publisher>Revised and Expanded
<author><surname>Sluzky</surname> <given-names>V</given-names> </author><author><surname>Tamada</surname> <given-names>JA</given-names> </author><author><surname>Klibanov</surname> <given-names>AM</given-names> </author><author><surname>Langer</surname> <given-names>R</given-names> </author><title>Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces</title><source>Proc Natl Acad Sci U S A</source><year>1991</year><volume>88</volume><fpage>9377</fpage><lpage>9381</lpage>
<author><surname>Bakaysa</surname> <given-names>DL</given-names> </author><author><surname>Radziuk</surname> <given-names>J</given-names> </author><author><surname>Havel</surname> <given-names>HA</given-names> </author><title>Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: dissociation of a protein&#8211;ligand complex</title><source>Protein Sci</source><year>1996</year><volume>5</volume><fpage>2521</fpage><lpage>2531</lpage>
<author><surname>Bhatnagar</surname> <given-names>S</given-names> </author><author><surname>Srivastava</surname> <given-names>D</given-names> </author><author><surname>Jayadev</surname> <given-names>MS</given-names> </author><author><surname>Dubey</surname> <given-names>AK</given-names> </author><title>Molecular variants and derivatives of insulin for improved glycemic control in diabetes</title><source>Prog Biophys Mol Biol</source><year>2006</year><volume>91</volume><fpage>199</fpage><lpage>228</lpage>
<author><surname>Vora</surname> <given-names>JP</given-names> </author><author><surname>Burch</surname> <given-names>A</given-names> </author><author><surname>Peters</surname> <given-names>JR</given-names> </author><author><surname>Owens</surname> <given-names>DR</given-names> </author><title>Absorption of radiolabelled soluble insulin in type 1 (insulin-dependent) diabetes: influence of subcutaneous blood flow and anthropometry</title><source>Diabet Med</source><year>1993</year><volume>10</volume><fpage>736</fpage><lpage>743</lpage>
<author><surname>Vora</surname> <given-names>JP</given-names> </author><author><surname>Burch</surname> <given-names>A</given-names> </author><author><surname>Peters</surname> <given-names>JR</given-names> </author><author><surname>Owens</surname> <given-names>DR</given-names> </author><title>Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry</title><source>Diabetes Care</source><year>1992</year><volume>15</volume><fpage>1484</fpage><lpage>1493</lpage>
<author><surname>Clauson</surname> <given-names>PG</given-names> </author><author><surname>Linde</surname> <given-names>B</given-names> </author><title>Absorption of rapid-acting insulin in obese and nonobese NIDDM patients</title><source>Diabetes Care</source><year>1995</year><volume>18</volume><fpage>986</fpage><lpage>991</lpage>
<author><surname>ter Braak</surname> <given-names>EW</given-names> </author><author><surname>Woodworth</surname> <given-names>JR</given-names> </author><author><surname>Bianchi</surname> <given-names>R</given-names> </author><title>Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin</title><source>Diabetes Care</source><year>1996</year><volume>19</volume><fpage>1437</fpage><lpage>1440</lpage>
<author><surname>Bergenstal</surname> <given-names>RM</given-names> </author><author><surname>Johnson</surname> <given-names>M</given-names> </author><author><surname>Powers</surname> <given-names>MA</given-names> </author><title>Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine</title><source>Diabetes Care</source><year>2008</year><volume>31</volume><fpage>1305</fpage><lpage>1310</lpage>